MedPath

Rocapuldencel-T

Generic Name
Rocapuldencel-T
Drug Type
Biotech
Unique Ingredient Identifier
8I9S6401XZ

Overview

Rocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer).

Background

Rocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Phase 2
Terminated
Posted: 2011/12/01
Sponsor:
Argos Therapeutics

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath